AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citius Pharmaceuticals Plunges 16.79% on Analyst Price Target Cut
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jun 10, 2025 4:30 am ET1min read
On June 10, 2025,
Inc. (NASDAQ:CTXR) experienced a significant drop of 16.79% in pre-market trading, marking a notable decline in its stock price.Citius Pharmaceuticals has been in the spotlight recently due to several key developments. The company announced a distribution services agreement, which initially boosted its stock price. This agreement is expected to enhance the company's commercialization efforts for its critical care products.
However, analysts at H.C. Wainwright revised their price target for
Pharmaceuticals, lowering it from $100 to $4 while maintaining a Buy rating. This revision reflects the market's cautious outlook on the company's future performance, despite the recent positive developments.Additionally, Citius Pharmaceuticals has seen significant volatility in its stock price, with shares soaring by as much as 121.5% in a single session. This volatility underscores the speculative nature of the company's stock, which can be influenced by both positive and negative news.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Metallus shares plunge 6.73% as investor concerns over earnings volatility and sector risks grow
Dec.22 2025
Annexon (ANNX) Surges 7.26% in Pre-Market Trading After S&P Biotechnology Index Inclusion
Dec.22 2025
Aeva Technologies Inc. surges 7.69% on strategic partnership with major automaker
Dec.22 2025
Oracle shares surge 6.63% on OpenAI rebuttal and healthcare contracts
Dec.22 2025
Broadcom Inc. (NASDAQ:AVGO) surges 3.18% on analyst upgrades amid AI growth optimism
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet